首页> 外文期刊>Journal of managed care pharmacy : >Adherence to statins in primary prevention: Yearly adherence changes and outcomes
【24h】

Adherence to statins in primary prevention: Yearly adherence changes and outcomes

机译:在一级预防中坚持他汀类药物:每年的依从性变化和结果

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Adherence to statins in real-world practice settings is known to be suboptimal. However, less is known about how adherence changes over time and whether changes in adherence are associated with adverse cardiovascular (CV) outcomes. OBJECTIVES: To (a) characterize yearly changes in adherence among initially adherent patients taking statins for primary prevention and (b) assess the association between changes in statin adherence with subsequent risk of CV events. METHODS: A 10% random sample of the IMS LifeLink Health Plan Claims Database covering the time period from July 1, 1997, to December 31, 2008, was used to identify a cohort of primary prevention statin users. Adherence was estimated in yearly segments beginning with the index statin prescription using proportion of days covered (PDC). PDC was categorized into 3 levels: PDC ≥ 0.80, 0.20 ≤ PDC < 0.80, PDC < 0.20. Patients were excluded if they experienced CV events or had PDC < 0.80 in their first year of statin exposure. Descriptive statistics were used to explore proportions of the cohort in each PDC category during each year. Cox-proportional hazards models were used to estimate the 5-year CV event risk associated with yearly adherence transitions. RESULTS: Of the 11,126 patients beginning at the highest level of adherence (PDC ≥ 0.80) in year 1, 70% remained at this level in year 2. Of those in this level during year 2, 73% remained at this level in year 3. 828 (7.44%) experienced a CV event during their observable follow-up time. It was found that those who transitioned from the highest to the lowest level of adherence in year 2 (PDC < 0.20) experienced 2.26 greater CV event hazard (P < 0.0001). Adjusting for year 2 adherence, patients at the lowest level in year 3 experienced a 271% increase in CV hazard (P < 0.0001), as compared with the highest level of adherence. CONCLUSION: This study found that patients' adherence levels tend to decline over time, and a transition to levels of adherence lower than a PDC of 80% was associated with increased risk of CV events. These results are useful in the context of targeting interventions that aim to improve patients' adherence.
机译:背景:在现实世界的实践环境中坚持他汀类药物是次优的。但是,关于依从性如何随时间变化以及依从性的变化是否与不良心血管(CV)结果相关的了解还很少。目的:(a)表征服用他汀类药物作为一级预防的最初依从性患者中依从性的年度变化,以及(b)评估他汀类药物依从性变化与随后的心血管事件风险之间的关联。方法:使用1997年7月1日至2008年12月31日期间的IMS LifeLink健康计划索赔数据库的10%随机样本来确定一组主要的他汀类药物使用者。从使用他汀类药物指数开始的年度细分(使用覆盖天数(PDC))进行估算。 PDC分为3个级别:PDC≥0.80、0.20≤PDC <0.80,PDC <0.20。如果他汀类药物暴露的第一年发生心血管事件或PDC <0.80,则排除患者。描述性统计数据用于探讨每年PDC类别中同类群组的比例。使用Cox比例风险模型估算与每年依从性转变相关的5年CV事件风险。结果:在第1年开始的最高依从性(PDC≥0.80)的11,126名患者中,有70%在第2年保持在该水平。在第2年中处于该水平的患者中,有73%在第3年保持在该水平。 828(7.44%)在他们可观察的随访时间内经历了一次简历事件。研究发现,在第2年从最高依从性转变为最低依从性的患者(PDC <0.20)遇到的CV事件危险性高2.26(P <0.0001)。调整第2年的依从性后,与最高依从性水平相比,第3年处于最低水平的患者的CV危险增加了271%(P <0.0001)。结论:这项研究发现患者的依从性水平会随着时间的流逝而下降,并且向依从性水平的转变(低于PDC的80%)会增加CV事件的风险。这些结果在针对旨在改善患者依从性的干预措施的背景下很有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号